(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on a new Milliman report on insulin coverage in Medicare Part D. A new report conducted by the actuarial firm Milliman, “A Summary of Insulin Coverage in
(Washington, D.C.) – Today, the Pharmaceutical Care Management Association (PCMA), the national association representing pharmacy benefit managers (PBMs), fought to protect access to affordable, quality prescription drug coverage in front of the United States Supreme Court in oral arguments for Rutledge
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the final Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs rule: “PCMA applauds CMS for delaying the
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. P&T COMMITTEES FOLLOW THE SCIENCE… Covering effective drugs for the broad
The independent pharmacy lobby is urging state legislatures to enact new legislation targeting pharmacy benefit managers (PBMs) that would increase fees and/or add surcharges to transactions with pharmacies. This is based upon two arguments: 1) that independent pharmacies are becoming
(Washington, D.C.) — The Pharmaceutical Care Management Association’s (PCMA) podcast, The Pharmacy Benefit, today released a new episode, “The Importance of PBMs in Health Care Costs,” which highlights the important role pharmacy benefit managers, PBMs, play in lowering prescription drug costs amid the Federal
New Milliman Analysis Shows Medicare Part D Proposed Rule Could Increase Premiums More than It Saves in Cost Sharing for Majority of Beneficiaries (Washington, D.C.) — A new report, “Medicare Part D Pharmacy Price Concessions at the Point of Sale, Potential Impacts
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on new National Health Expenditure (NHE) data from the Centers for Medicare & Medicaid Services: The latest NHE survey shows that the retail prescription drug net price index declined
Insulin list prices have escalated dramatically during the past 5-10 years. This is due to only three manufacturers controlling the market, the lack of alternative insulins, and manufacturer abuse of patent extensions. PBMs drive competition using drug formularies and rebates.
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. RX DRUG AFFORDABILITY BOARDS: NO PRICE SETTING & COME ONE, COME
©2024 PCMA. All Rights Reserved.
